New Partnership with Hetero Drugs

Enric Villagran, CEO, MBA, MSc – November 12, 2020

Meeting its Strategic Development Plan objectives for 2020-2025, NatrellePharma has finalised a Marketing Holder and Commercialisation agreement for Cuba, Bolivia and Uruguay with Hetero Drugs Pvt. Ltd. -India, one of the largest companies worldwide, recognised for its strength in Research & Development, commercialisation and manufacturing of over 300 products and the best international certifications:

Hetero Drugs Pvt is the largest producer of antiretroviral medicines for the treatment of HIV/AIDS. Backed by more than 25 years of experience in the pharmaceutical industry, Hetero’s strategic areas of business extend via API, generics, biosimilars, personalised pharmaceutical services and branded generics.

Hetero has 36 cutting edge manufacturing warehouses strategically located around the world, which are audited and approved by regulating authorities such as the FDA from EE.EE. UE, TGA-Australia, MCC-South-Africa and others. Its portfolio includes more than 300 products that make up the main therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology, Immunology etc.

Its recent association with Gilead and Astra Zeneca has converted it into a global leader.

With a strong global presence in more than 126 countries, it focuses on ensuring medicine is accessible to patients in the whole world. NatrellePharma has been chosen as the designated partner to undertake the future challenges in the markets described with biosimilar products:

 CUBA: Rituximab, Darbepoetina, Adalimumab, Bevasizumab

BOLIVIA & URUGUAY: Ritunatrelle, Darbenatrelle, Adalinatatrelle and Bevanatrelle